SCHEMBL20604102

SCHEMBL20604102

Cc1c(C(=O)O)nnn1-c1cccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.61
MAPT P10636 2/20 0.48
GSK3B P49841 1/20 0.46
WNT3A P56704 1/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.44
TP53 P04637 2/20 0.44
ALOX12 P18054 1/20 0.44
SPR P35270 1/20 0.43
PTGS2 P35354 1/20 0.43
PFKFB3 Q16875 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MYC P01106 1/20 0.41
NR4A1 P22736 1/20 0.40
NR4A2 P43354 1/20 0.40
NR4A3 Q92570 1/20 0.40
MEN1 O00255 1/20 0.40
PRNP P04156 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17321553 0.82 HTT (0.69) HTTMAPTGSK3BWNT3AALDH1A1
SCHEMBL23611893 0.81 HTT (0.52) HTTMAPTGSK3BWNT3ATP53
SCHEMBL3456998 0.79 HTT (0.65) HTTMAPTGSK3BWNT3AALDH1A1
SCHEMBL20604188 0.79 HTT (0.60) HTTMAPTGSK3BWNT3AALDH1A1
SCHEMBL2219241 0.79 HTT (0.65) HTTMAPTGSK3BWNT3ATP53
SCHEMBL30038081 0.79 HTT (0.65) HTTMAPTGSK3BWNT3ATP53
SCHEMBL23626173 0.79 HTT (0.50) HTTMAPTALDH1A1HPGDHSD17B10
SCHEMBL20604199 0.78 HTT (0.63) HTTMAPTGSK3BWNT3AALDH1A1
SCHEMBL20604293 0.78 HTT (0.63) HTTMAPTGSK3BWNT3AALDH1A1
SCHEMBL20604118 0.77 WNT3A (0.80) GSK3BWNT3AHPGDSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV OF MARYLAND BALTIMORE (US) 2026-05-21 US disclosed
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2025-08-05 US disclosed
EP-3423452-B1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIV MARYLAND (US) 2025-05-07 EP disclosed
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2024-06-27 US disclosed
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-23 US disclosed
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease UNIVERSITY OF MARYLAND, BALTIMORE (US) 2021-01-05 US disclosed
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE UNIVERSITY OF MARYLAND, BALTIMORE 2020-09-24 US disclosed
US-10723715-B2 2020-07-28 US disclosed
US-20190071424-A1 WNT Signaling Pathway Inhibitors for Treatments of Disease UNIVERSITY OF MARYLAND, BALTIMORE 2019-03-07 US disclosed
EP-3423452-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE University of Maryland, Baltimore (US) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882841-B2 Wnt signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A HTT 1192/4885MAPT 554/4885GSK3B 8/4885
US-20200299261-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A HTT 1192/4885MAPT 554/4885GSK3B 8/4885
US-12378220-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A HTT 1192/4885MAPT 554/4885GSK3B 8/4885
US-20190071424-A1 WNT Signaling Pathway Inhibitors for Treatments of Disease WNT1, CTNNB1, WNT3A HTT 1192/4885MAPT 554/4885GSK3B 8/4885
US-11655233-B2 WNT signaling pathway inhibitors for treatments of disease WNT1, CTNNB1, WNT3A HTT 1192/4885MAPT 554/4885GSK3B 8/4885
US-20260138966-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE CTNNB1, WNT1, CTNND1 HTT 1107/4885MAPT 4770/4885GSK3B 11/4885
US-20240208927-A1 WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE WNT1, CTNNB1, WNT3A HTT 1192/4885MAPT 554/4885GSK3B 8/4885
US-10723715-B2 CTNNB1, WNT1, CTNNBL1 HTT 1668/4885MAPT 1267/4885GSK3B 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.